China Pharma Holdings (CPHI)

$1.87 +0.22 (13.43%)
Market Cap 5.38M
Revenue (ttm) 4.53M
Net Income (ttm) -4.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -104.64%
Debt to Equity Ratio 0.31
Volume 382,942
Avg Vol 116,991
Day's Range N/A - N/A
Shares Out 3.26M
Stochastic %K 62%
Beta 0.77
Analysts Strong Buy
Price Target $4.50

Latest News on CPHI

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

Apr 4, 2025, 4:05 PM EDT - 21 days ago

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville

Dec 18, 2024, 8:30 AM EST - 4 months ago

China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville

China Pharma Announces the Entry of "At-The-Market" Equity Offering

Dec 13, 2024, 8:00 AM EST - 4 months ago

China Pharma Announces the Entry of "At-The-Market" Equity Offering

China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025

Aug 19, 2024, 8:00 AM EDT - 8 months ago

China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025

China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split

Feb 23, 2024, 4:05 PM EST - 1 year ago

China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

Nov 29, 2023, 8:00 AM EST - 1 year ago

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs

Aug 9, 2023, 8:30 AM EDT - 1 year ago

China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs

China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

Dec 28, 2022, 8:00 AM EST - 2 years ago

China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

Dec 15, 2022, 8:00 AM EST - 2 years ago

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project

Dec 5, 2022, 8:00 AM EST - 2 years ago

China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project

China Pharma Announces Receipt of Noncompliance Notice from NYSE American

Dec 2, 2022, 4:10 PM EST - 2 years ago

China Pharma Announces Receipt of Noncompliance Notice from NYSE American

China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency

Oct 1, 2022, 10:05 PM EDT - 2 years ago

China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency

China Pharma Announced the Submission of a Plan of Compliance to NYSE American

Jul 18, 2022, 8:00 AM EDT - 3 years ago

China Pharma Announced the Submission of a Plan of Compliance to NYSE American

China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results

Mar 31, 2022, 8:00 AM EDT - 3 years ago

China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results

China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

Nov 12, 2021, 4:30 PM EST - 3 years ago

China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

Aug 13, 2021, 4:30 PM EDT - 4 years ago

China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

Aug 5, 2021, 9:00 AM EDT - 4 years ago

China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

China Pharma to Launch Highly Purified NMN+PQQ Product

Jun 9, 2021, 8:00 AM EDT - 4 years ago

China Pharma to Launch Highly Purified NMN+PQQ Product

China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue

May 14, 2021, 4:30 PM EDT - 4 years ago

China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue

China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port

Apr 19, 2021, 8:30 AM EDT - 4 years ago

China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port

China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results

Mar 26, 2021, 5:00 PM EDT - 4 years ago

China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results

China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript

Mar 31, 2020, 9:36 AM EDT - 5 years ago

China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript

China Pharma's (CPHI) CEO Zhilin Li on Q2 2019 Results - Earnings Call Transcript

Aug 15, 2019, 1:13 PM EDT - 6 years ago

China Pharma's (CPHI) CEO Zhilin Li on Q2 2019 Results - Earnings Call Transcript

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2019 Results - Earnings Call Transcript

May 15, 2019, 10:31 AM EDT - 6 years ago

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2019 Results - Earnings Call Transcript

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q4 2018 Results - Earnings Call Transcript

Mar 29, 2019, 1:16 PM EDT - 6 years ago

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q4 2018 Results - Earnings Call Transcript